GLPwatch
Autoinjector Device Assessment Study
NCT02349802 · Completed
Last updated 2026-05-28This study tests a new autoinjector device in healthy volunteers to see how often it fails to deliver medication properly.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 3,052 people
Who can join Ages 18+ · all sexes Healthy volunteers accepted.
Timeline Started 2013-02 · est. completion 2013-12
Where 2 sites · United States
What this study is testing ClinicalTrials.gov NCT02349802 ↗
Description as written by the study sponsor.
Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
Treatments tested
- Auto-injector with exenatide suspension Drug
A flexible study design to accommodate multiple cohorts.
- Syringe with exenatide suspension Drug
A flexible study design to accommodate multiple cohorts.
| Main thing measured | Number of device-related failure injections |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Healthy Subjects |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02349802 ↗